TPG Capital, the private equity platform of global alternative asset management firm TPG, is to acquire a majority interest in DOC Generici, a manufacturer of generic pharmaceuticals in Italy, from ICG and Merieux Equity Partners.
As part of the transaction, Karthic Jayaraman, Partner at TPG Capital, and TPG Capital Principal Ravi Umarji will join DOC Generici’s Board of Directors.
Mediobanca, Morgan Stanley & Co International plc, and Deutsche Bank acted as financial advisors to TPG Capital, and Latham & Watkins served as legal counsel. Barclay’s and BNP served as financial advisors to DOC Generici, and Gattai served as legal counsel.
Read more: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.